IM Cannabis
Market Cap
CA$400.1m
Last Updated
2021/01/22 00:19 UTC
Data Sources
Company Financials +
Executive Summary
IM Cannabis Corp. focuses on breeding, growing, and supply of medical cannabis products in Israel and Germany. More Details
Rewards
Risk Analysis
Snowflake Analysis
Adequate balance sheet with limited growth.
Share Price & News
How has IM Cannabis's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: IMCC is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: IMCC's weekly volatility has decreased from 18% to 11% over the past year.
Market Performance
7 Day Return
-4.7%
IMCC
3.0%
CA Pharmaceuticals
0.7%
CA Market
1 Year Return
390.0%
IMCC
49.4%
CA Pharmaceuticals
2.1%
CA Market
Return vs Industry: IMCC exceeded the Canadian Pharmaceuticals industry which returned 52.2% over the past year.
Return vs Market: IMCC exceeded the Canadian Market which returned 2% over the past year.
Shareholder returns
| IMCC | Industry | Market | |
|---|---|---|---|
| 7 Day | -4.7% | 3.0% | 0.7% |
| 30 Day | -2.0% | 32.8% | 4.6% |
| 90 Day | 44.1% | 71.2% | 13.5% |
| 1 Year | 390.0%390.0% | 49.4%49.4% | 5.8%2.1% |
| 3 Year | n/a | -51.7%-52.4% | 13.9%3.1% |
| 5 Year | n/a | 413.7%410.0% | 67.3%41.6% |
Long-Term Price Volatility Vs. Market
How volatile is IM Cannabis's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
What Percentage Of IM Cannabis Corp. (CSE:IMCC) Shares Do Insiders Own?2 months ago | Simply Wall St
IM Cannabis (CSE:IMCC) Shareholders Have Enjoyed An Impressive 287% Share Price Gain3 months ago | Simply Wall St
What Percentage Of IM Cannabis Corp. (CSE:IMCC) Shares Do Insiders Own?Valuation
Is IM Cannabis undervalued compared to its fair value and its price relative to the market?
13.8x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate IMCC's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate IMCC's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: IMCC is unprofitable, so we can't compare its PE Ratio to the CA Pharmaceuticals industry average.
PE vs Market: IMCC is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IMCC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: IMCC is overvalued based on its PB Ratio (14.1x) compared to the CA Pharmaceuticals industry average (2.8x).
Next Steps
Future Growth
How is IM Cannabis forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
38.5%
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if IMCC's forecast earnings growth is above the savings rate (1.5%).
Earnings vs Market: Insufficient data to determine if IMCC's earnings are forecast to grow faster than the Canadian market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: IMCC's revenue (38.5% per year) is forecast to grow faster than the Canadian market (7.9% per year).
High Growth Revenue: IMCC's revenue (38.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if IMCC's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has IM Cannabis performed over the past 5 years?
14.4%
Last years earnings growth
Earnings and Revenue History
Quality Earnings: IMCC is currently unprofitable.
Growing Profit Margin: IMCC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if IMCC's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare IMCC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IMCC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-61.1%).
Return on Equity
High ROE: IMCC has a negative Return on Equity (-23.33%), as it is currently unprofitable.
Next Steps
Financial Health
How is IM Cannabis's financial position?
Financial Position Analysis
Short Term Liabilities: IMCC's short term assets (CA$30.2M) exceed its short term liabilities (CA$4.0M).
Long Term Liabilities: IMCC's short term assets (CA$30.2M) exceed its long term liabilities (CA$5.4M).
Debt to Equity History and Analysis
Debt Level: IMCC is debt free.
Reducing Debt: IMCC had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IMCC has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: IMCC has less than a year of cash runway if free cash flow continues to reduce at historical rates of 87.5% each year
Next Steps
Dividend
What is IM Cannabis's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IMCC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IMCC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IMCC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IMCC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IMCC's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.0yrs
Average management tenure
CEO
Oren Shuster
1.25yrs
Tenure
Mr. Oren Shuster serves as the Co-owner of IMC Ltd. Mr. Shuster serves as Chief Executive Officer and Director of IM Cannabis Corp. since October 11, 2019.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.25yrs | no data | 22.83% CA$ 91.3m | |
| Chief Financial Officer | no data | no data | 0.030% CA$ 119.1k | |
| Managing Director Israel Operation | 0.58yr | no data | no data | |
| Corporate Secretary | no data | no data | no data | |
| Chief Executive Officer of German Operation | 1yr | no data | 0.13% CA$ 525.0k |
1.0yrs
Average Tenure
Experienced Management: IMCC's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.25yrs | no data | 22.83% CA$ 91.3m | |
| Director | 2.25yrs | no data | 0.69% CA$ 2.7m | |
| Independent Director | 0.83yr | no data | no data | |
| Independent Chairman | 2yrs | no data | 0.85% CA$ 3.4m | |
| Director | 0.83yr | no data | 20.35% CA$ 81.4m |
1.3yrs
Average Tenure
Experienced Board: IMCC's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.8%.
Top Shareholders
Company Information
IM Cannabis Corp.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: IM Cannabis Corp.
- Ticker: IMCC
- Exchange: CNSX
- Founded: NaN
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$400.077m
- Shares outstanding: 160.03m
- Website: https://www.imcannabis.com
Number of Employees
Location
- IM Cannabis Corp.
- Kibbutz
- Glil Yam
- Tel Aviv
- Israel
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| IMCC | CNSX (Canadian National Stock Exchange) | Yes | Common Shares | CA | CAD | Nov 2019 |
| IMCN.F | OTCPK (Pink Sheets LLC) | Yes | Common Shares | US | USD | Nov 2019 |
Biography
IM Cannabis Corp. focuses on breeding, growing, and supply of medical cannabis products in Israel and Germany. Its products include strains and oils. The company also offers its intellectual property relat...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/22 00:19 |
| End of Day Share Price | 2021/01/21 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.